Obalon Therapeutics Inc (OBLN) VP Matthew Norwood Acquires 1,000 Shares
Obalon Therapeutics Inc (NASDAQ:OBLN) VP Matthew Norwood bought 1,000 shares of the firm’s stock in a transaction on Wednesday, October 12th. The stock was acquired at an average price of $15.00 per share, for a total transaction of $15,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Shares of Obalon Therapeutics Inc (NASDAQ:OBLN) opened at 13.92 on Thursday. The stock’s 50 day moving average price is $14.76 and its 200-day moving average price is $14.76. Obalon Therapeutics Inc has a 52 week low of $13.92 and a 52 week high of $15.88.
Obalon Therapeutics Company Profile
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/13/obalon-therapeutics-inc-obln-vp-matthew-norwood-acquires-1000-shares.html
Obalon Therapeutics, Inc is a commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company’s product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients.
Receive News & Ratings for Obalon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obalon Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.